Literature DB >> 25674484

Simple clinical indicators for early psoriatic arthritis detection.

Francesco Caso1, Luisa Costa2, Mariangela Atteno3, Antonio Del Puente3, Luca Cantarini4, Ennio Lubrano5, Raffaele Scarpa3.   

Abstract

BACKGROUND: Diagnosis of psoriatic arthritis (PsA), in a period of 12 months from the onset of the first articular episode, permits of identifying the early form defined as "early PsA". The recognition of the disease in this phase leads to better outcome. The aim of this study was to identify peculiar clinical and/or laboratory findings that could be useful for the diagnosis of "early PsA".
FINDINGS: Thirty-five patients with early onset of arthritis were observed. The following data were collected for each patient: family and personal history, physical examination, tender and swollen joint counts (TJC, SJC), tender entheseal count, presence of dactylitis and low back pain (LBP), and laboratory tests. Among the 35 total patients, 24 showed skin and/or nail psoriasis or a family history of psoriasis. The remaining 11 patients showed absence of concomitant or previous psoriasis and/or familiarity for psoriasis. The comparison between the two groups showed that patients with psoriasis had a significant presence of LBP, dactylitis and enthesitis than patients with psoriasis.
CONCLUSIONS: The study confirms that the distinctive clinical findings of PsA is psoriasis, but also LBP, dactylitis and enthesitis have a relevant role in early identification. A low number of SJC and TJC are frequently observed in early phases of PsA than in other forms of early arthritis. These aspects could be mostly helpful when psoriasis is not detected or can follow arthritis in absence of familiar positivity, making difficult PsA diagnosis. In conclusion, careful medical history, clinical examination and first-level laboratory investigations are useful to characterize early phases of PsA.

Entities:  

Keywords:  Dactylitis; Early psoriatic arthritis; Enthesitis; Low-back pain; Psoriasis

Year:  2014        PMID: 25674484      PMCID: PMC4320171          DOI: 10.1186/2193-1801-3-759

Source DB:  PubMed          Journal:  Springerplus        ISSN: 2193-1801


Introduction

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy, belonging to the spondyloarthritic area, usually associated with skin and/or nail psoriasis or with its familiarity (Moll & Wright 1973). Other clinical sites such as the bowel, eye and cardiovascular system be variably involved (Scarpa et al. 2000; Niccoli et al. 2012; Shang et al. 2012; Costa et al. 2012). The progress in the knowledge of new imaging techniques has changed the diagnostic approach to this condition (Soscia et al. 2012; Tan et al. 2014; Poggenborg et al. 2014; Gladman 2012), even if final diagnosis mainly relies on clinical evaluation performed by a rheumatologist. It usually refers to a characteristic presentation of joints, spine and enthesis inflammatory findings, a negative rheumatoid factor in presence of psoriasis or its familiarity (Duarte et al. 2012). Diagnosis of PsA, in a period of 12 months from the onset of the first articular episode, permits of identifying the early form defined as “early PsA”. The recognition of the disease in this phase leads to better outcome. However, in the context of clinical practice, in early phases it is complex to rule out other inflammatory diseases, such as rheumatoid arthritis, undifferentiated arthritis and other spondyloarthritides (Gladman 2012). In 2006, a set of classification criteria was developed by the CASPAR (ClASsification criteria for Psoriatic ARthritis) Study Group, with the aim of identifying standardized and homogeneous cohorts of PsA patients in clinical research context (Duarte et al. 2012). Although CASPAR Criteria do not represent diagnostic criteria, these have had a wide consensus, due to high specificity (98.7%) and good sensitivity (91.4%), confirmed also retrospectively (Taylor et al. 2006; Tillett et al. 2012). Furthermore, CASPAR criteria have been applied in some studies on early PsA showing good sensitivity (88.7%) and high specificity (99.1%), but data are still few (van den Berg et al. 2012; D'Angelo et al. 2009). While a distinctive clinical finding of PsA is psoriasis, dactylitis, enthesitis and inflammatory low-back pain should be present without a pathognomonic role. In Addition, no laboratory findings can be helpful in addressing PsA diagnosis. The aim of this study was to identify peculiar clinical and/or laboratory findings that could be useful for the diagnosis of “early PsA”.

Patients and methods

In 7-month period, 35 patients (M/W: 7/28; mean age: 47.0 years, range: 17–78 years) with early onset of arthritis (within 12 weeks of onset), attending Rheumatology Unit of University Federico II of Naples, were observed. The average onset of arthritis was 5.6 months (range 2–12 months). The following data were collected for each patient: family and personal history, including familiar and/or previous psoriasis, physical examination, tender and swollen joint counts (TJC, SJC), tender entheseal count, presence of dactylitis and low back pain. Evaluation of rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (anti-CCP) and inflammatory indices, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), were performed. Written informed consent was obtained from the patient for the publication of this report. Statistical analysis was performed using the SPSS software, version 18 (SPSS inc, Chicago, Ill). All variables were normally distributed. Analysis of variance (ANOVA) was used to assess differences between group means.

Results

Among the 35 total patients, twenty-four showed skin and/or nail psoriasis or a family history of psoriasis (M/W: 5/19, mean age 44.9 years, range 17–73 years; mean duration of articular disease 5.8 months, range 2–12). The remaining eleven patients showed absence of concomitant or previous psoriasis and/or familiarity for psoriasis (M/W: 2/9, mean age 51.5 years, range 28–78 years; mean disease duration 5.0 months, range 2–12). The comparison between the two groups (Table 1) showed that patients with psoriasis had a significant presence of inflammatory back pain, dactylitis and enthesitis (respectively p <0.001, p <0.001 and p <0.01), whereas patients without psoriasis showed a greater TJC (p <0.001) SJC (p <0.001), and RF positivity (p <0.01) than patients with psoriasis. In the group of patients with psoriasis, the application of CASPAR criteria led to a PsA diagnosis in all the patients, while none of the patients in the group without psoriasis was satisfying these criteria.
Table 1

Clinical and laboratory findings of early arthritis patients with and without psoriasis

Early arthritis patients with psoriasis (n. 24)Early arthritis patients without psoriasis (n.11) p
TJC6.0 (0–28)13.45 (8–24)<0.05
SJC0.9 (0–5.0)2.54 (0–10)<0.05
LBP, n (%)16; 66.6%0<0.001
Dactylitis, n (%)11; 45,8%0<0.001
Enthesitis, n (%)5; 20.8%0<0.01
ESR > 15 mm/1 h, n (%)6; 25%11; 100%ns
CRP > 0.5 mg/dL, n (%)6; 25%11; 100%ns
RF positivity, n (%)09; 81.8%0.01
Anti-CCP positivity, n (%)04; 36.3%ns
Uveitis, n (%)3; 12.5%0ns

Data expressed as mean ± range, unless otherwise indicated.

Clinical and laboratory findings of early arthritis patients with and without psoriasis Data expressed as mean ± range, unless otherwise indicated.

Conclusions

For a long time, PsA has been considered a low grade inflammatory condition and only most recently increasing data have provided evidence on the severe impact of this disease, establishing at same time the importance of an early diagnosis and treatment (Gladman 2012; Scarpa et al. 2011). The CASPAR criteria consist of established inflammatory articular disease with at least a sum of three points from the following: current psoriasis (2 points), a history of psoriasis (1 point), a family history of psoriasis (unless current psoriasis was present or there was a history of psoriasis; 1 point), dactylitis (1 point), juxta-articular new bone formation (1 point), RF negativity (1 point), and nail dystrophy (1 point) (Taylor et al. 2006). In this study, co-occurrence of inflammatory back pain and dactylitis were present respectively in above 46% and 66% of patients with psoriasis and were very helpful in addressing early PsA diagnosis. Enthesitis was detected in above 21% of patients with psoriasis. Patients with psoriasis showed a lower number of TJC and SJC, than patients without psoriasis; previous episode of uveitis was referred in three of 24 patients with psoriasis and in no one of patients without psoriasis. With regard to laboratory findings, all the patients without psoriasis showed increased ESR and C-RP, RF and anti-CCP positivity was found in above 82% and 36% of them. Differently, only 25% of patients with psoriasis showed increase of ESR and CRP and no one RF and anti-CCP positivity. This study confirms that the distinctive clinical findings of PsA is psoriasis, but also inflammatory low-back pain, dactylitis and enthesitis have a relevant role in early identification. A low number of SJC and TJC, as well anti-CCP and RF negativity and no increase of ESR and C-RP are most frequently observed in early phases of PsA than in other forms of early arthritis. These aspects could be mostly helpful when psoriasis is not detected or can follow arthritis in absence of familiar positivity, making difficult PsA diagnosis. The study shows several limitations: mainly the number of patients which is low and for this reason the results need to be supported by studies on larger populations. Although the progress in the knowledge of new imaging techniques has changed the diagnostic approach to PsA (Soscia et al. 2012; Tan et al. 2014; Poggenborg et al. 2014; Gladman 2012), but PsA diagnosis still relies mainly on clinical evaluation. Therefore, the results of the present observation may be interesting from practical point of view. The key message is that careful medical history, clinical examination and first-level laboratory investigations such as ESR, CRP, anti-CCP and FR are reasonably useful to characterize early phases of PsA. Delay in PsA diagnosis significantly contributes to poor outcome of the patient, so early identification of simple and helpful indicators could allow for the characterization of “early PsA”.
  15 in total

1.  New developments in magnetic resonance imaging of the nail unit.

Authors:  Ernesto Soscia; Cesare Sirignano; Onofrio Catalano; Mariangela Atteno; Luisa Costa; Francesco Caso; Rosario Peluso; Vincenzo Bruner; Maria Maddalena Aquino; Antonio Del Puente; Marco Salvatore; Raffaele Scarpa
Journal:  J Rheumatol Suppl       Date:  2012-07

Review 2.  Psoriatic arthritis.

Authors:  J M Moll; V Wright
Journal:  Semin Arthritis Rheum       Date:  1973       Impact factor: 5.532

3.  Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study.

Authors:  Luisa Costa; Francesco Caso; Lanfranco D'Elia; Mariangela Atteno; Rosario Peluso; Antonio Del Puente; Pasquale Strazzullo; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2011-11-24       Impact factor: 2.980

4.  Enthesitis in patients with psoriatic arthritis, axial spondyloarthritis and healthy subjects assessed by 'head-to-toe' whole-body MRI and clinical examination.

Authors:  René Panduro Poggenborg; Iris Eshed; Mikkel Østergaard; Inge Juul Sørensen; Jakob M Møller; Ole Rintek Madsen; Susanne Juhl Pedersen
Journal:  Ann Rheum Dis       Date:  2014-01-03       Impact factor: 19.103

5.  The ClASsification for Psoriatic ARthritis (CASPAR) criteria--a retrospective feasibility, sensitivity, and specificity study.

Authors:  William Tillett; Luisa Costa; Deepak Jadon; Dinny Wallis; Charlotte Cavill; Jessica McHugh; Eleanor Korendowych; Neil McHugh
Journal:  J Rheumatol       Date:  2011-11-15       Impact factor: 4.666

6.  Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms.

Authors:  R Scarpa; F Manguso; A D'Arienzo; F P D'Armiento; C Astarita; G Mazzacca; F Ayala
Journal:  J Rheumatol       Date:  2000-05       Impact factor: 4.666

7.  Increase in ventricular-arterial stiffness in patients with psoriatic arthritis.

Authors:  Qing Shang; Lai-Shan Tam; John E Sanderson; Jing-Ping Sun; Edmund Kwok-Ming Li; Cheuk-Man Yu
Journal:  Rheumatology (Oxford)       Date:  2012-08-25       Impact factor: 7.580

8.  Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis.

Authors:  Salvatore D'Angelo; Gianna Angela Mennillo; Maria Stefania Cutro; Pietro Leccese; Angelo Nigro; Angela Padula; Ignazio Olivieri
Journal:  J Rheumatol       Date:  2009-02-04       Impact factor: 4.666

9.  The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study.

Authors:  Raffaele Scarpa; Mariangela Atteno; Ennio Lubrano; Giuseppe Provenzano; Salvatore D'Angelo; Antonio Spadaro; Luisa Costa; Ignazio Olivieri
Journal:  Clin Rheumatol       Date:  2011-03-01       Impact factor: 2.980

10.  High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis.

Authors:  Ai Lyn Tan; Eiji Fukuba; Nicola Ann Halliday; Steven F Tanner; Paul Emery; Dennis McGonagle
Journal:  Ann Rheum Dis       Date:  2014-09-26       Impact factor: 19.103

View more
  11 in total

Review 1.  Psoriatic arthritis and psoriasis: differential diagnosis.

Authors:  Maddalena Napolitano; Francesco Caso; Raffaele Scarpa; Matteo Megna; Angela Patrì; Nicola Balato; Luisa Costa
Journal:  Clin Rheumatol       Date:  2016-05-07       Impact factor: 2.980

Review 2.  Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study.

Authors:  Francesco Caso; Antonio Del Puente; Francesca Oliviero; Rosario Peluso; Nicolò Girolimetto; Paolo Bottiglieri; Francesca Foglia; Carolina Benigno; Marco Tasso; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

3.  Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules".

Authors:  Matteo Megna; Anna Balato; Maddalena Napolitano; Lucia Gallo; Francesco Caso; Luisa Costa; Nicola Balato; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2018-04-11       Impact factor: 2.980

Review 4.  Apremilast in the treatment of psoriatic arthritis: a perspective review.

Authors:  Michael Reed; David Crosbie
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-01-20       Impact factor: 5.346

5.  Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.

Authors:  Maddalena Napolitano; Luisa Costa; Francesco Caso; Matteo Megna; Raffaele Scarpa; Nicola Balato; Fabio Ayala; Anna Balato
Journal:  Clin Rheumatol       Date:  2017-05-31       Impact factor: 2.980

6.  Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting.

Authors:  Luca Navarini; Luisa Costa; Marco Tasso; Maria Sole Chimenti; Damiano Currado; Giulia Lavinia Fonti; Massimo Ciccozzi; Domenico Paolo Emanuele Margiotta; Carolina Benigno; Erica De Martino; Roberto Perricone; Antonella Afeltra; Raffaele Scarpa; Francesco Caso
Journal:  Clin Rheumatol       Date:  2020-03-18       Impact factor: 2.980

Review 7.  Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management.

Authors:  Francesco Caso; Marco Tasso; Maria Sole Chimenti; Luca Navarini; Carlo Perricone; Nicolò Girolimetto; Rosario Peluso; Antonio Del Puente; Antonella Afeltra; Roberto Perricone; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

8.  Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study.

Authors:  Eleni Kampylafka; David Simon; Isabelle d'Oliveira; Christina Linz; Veronika Lerchen; Matthias Englbrecht; Juergen Rech; Arnd Kleyer; Michael Sticherling; Georg Schett; Axel J Hueber
Journal:  Arthritis Res Ther       Date:  2019-07-26       Impact factor: 5.156

Review 9.  Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.

Authors:  Luisa Costa; Carlo Perricone; Maria Sole Chimenti; Antonio Del Puente; Paolo Caso; Rosario Peluso; Paolo Bottiglieri; Raffaele Scarpa; Francesco Caso
Journal:  Drugs R D       Date:  2017-12

Review 10.  Evaluating Inflammatory Versus Mechanical Back Pain in Individuals with Psoriatic Arthritis: A Review of the Literature.

Authors:  Linda L Grinnell-Merrick; Eileen J Lydon; Amanda M Mixon; William Saalfeld
Journal:  Rheumatol Ther       Date:  2020-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.